Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

6.60
+0.760013.01%
Post-market: 6.920.3200+4.85%19:53 EDT
Volume:147.08K
Turnover:901.07K
Market Cap:3.35M
PE:-0.06
High:6.70
Open:5.75
Low:5.54
Close:5.84
52wk High:3,840.00
52wk Low:5.25
Shares:507.40K
Float Shares:507.20K
Volume Ratio:4.08
T/O Rate:29.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-118.4105
EPS(LYR):-2,427.8177
ROE:-106.98%
ROA:-53.08%
PB:0.26
PE(LYR):0.00

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:27 AM

Reuters
·
Jun 01

Top Premarket Decliners

MT Newswires Live
·
Jun 01

Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan

TIPRANKS
·
May 29

Clearmind Medicine files Japanese patent application for MEAI-based depression treatment

Reuters
·
May 29

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

TIPRANKS
·
May 26

Clearmind says Johns Hopkins IRB clears next stages of CMND-100 Phase I/II trial

Reuters
·
May 26

Clearmind Medicine Announces Johns Hopkins Irb Approval to Advance Cmnd-100 Phase I/Ii Clinical Trial to the Next Parts

THOMSON REUTERS
·
May 26

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
May 21

Clearmind Medicine Inc trading halted, news pending

TIPRANKS
·
May 21

Top Premarket Decliners

MT Newswires Live
·
May 19

Clearmind agrees to convert $600,000 notes into common shares at $0.3 each

Reuters
·
May 19

Clearmind Medicine announces 1-for-10 reverse share split

TIPRANKS
·
May 19

Clearmind Medicine to execute 1-for-10 reverse stock split May 21

Reuters
·
May 19

BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split

Reuters
·
May 19

Clearmind Medicine Announces 1-for-10 Reverse Share Split

THOMSON REUTERS
·
May 19

Clearmind Medicine to sell USD 600,000 convertible notes at 90% of face value

Reuters
·
May 19

Clearmind Medicine signs new research agreement with Yissum Research Development

TIPRANKS
·
May 18

Clearmind signs preclinical study of MEAI with tirzepatide in obese mice

Reuters
·
May 18

Clearmind Medicine Signs Agreement to Examine Meai in Combination and Sequencing With Tirzepatide Against Blockbuster Glp-1 Medications

THOMSON REUTERS
·
May 18

Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.

THOMSON REUTERS
·
May 15